In this study, the willingness of psychiatric inpatients to volunteer for research and their
capacity to consent to and distinguish between protocols offering different levels of risk and …

New arising technologies change the modes of interaction between companies and their
customers. So-called self-service technologies (SSTs) allow integrating customers as active …

Background Second line treatment for R/M CC continues to be a high unmet clinical need.
We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with …

Background Rivoceranib is an oral, selective tyrosine kinase inhibitor of VEGFR-2 with
demonstrated efficacy for gastric cancer in China. ANGEL was a global phase III study to evaluate …

Objective: Starting with the recommendations ofthe" Psychiatrie-Enquete", a current empirical
stock-taking was undertaken about the structure of care in psychiatric hospital units. …

Objective: to examinedrug treatmentpossibilities for tardive dyskinesia. In addtion the
authorevaluatedthe relationship between typeand dose of antipsychotic drugs. psychiatric …

4500 Background: In the first interim analysis of the randomized, multicenter, open-label,
phase 3 KEYNOTE-426 study (NCT02853331), treatment with pembro + axi significantly …

Background Homologous recombination repair (HRR) enables fault-free repair of double-stranded
DNA breaks. HRR deficiency is predicted to occur in around half of high-grade …

… Background: Poly-ADP-ribose polymerase (PARP) inhibition plus PD-(L)1 blockade has …
of 0−1, and without prior PARP or PD-(L)1 inhibitor therapy or progression on or ≤4 wks after …

Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …